Thursday, June 22, 2017| , Revance Therapeutics, Inc, , Atopic Derm, , Atopic Dermatitis , , Tattoo ,

DermWireTV: Revance Data, AD Updates, FDA Actions

A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated with somewhat reduced risk of stroke, hypertension, diabetes, and heart attack. Results of Phase 2 BELMONT study: 40U dose of Revanche's RT002 has a significantly longer duration of response,compared to onabotulinumtoxinA. And FDA warns on black henna tattoos.

Watch Video

Wednesday, June 07, 2017

DermWireTV: Derm Surgeries Top 10M; VCS Kicks Off; Tildrakizumab with FDA

Dermatologic surgical procedures continue to increase in popularity. Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016—up five percent from 2015 and up 31 percent since 2012. Results are presented in the 2016 American Society for Dermatologic Surgery (ASDS)Survey on Dermatologic Procedures. Vegas Cosmetic Surgery is underway at the Bellagio. The multispecialty program educates dermatologists, plastic surgeons, facial plastic surgeons, and oculoplastic surgeons. Following FDA clearance, the Clarify Medical Phototherapy System at-home UVB phototherapy system will be available to patients with chronic skin diseases in November.

Watch Video

Thursday, May 25, 2017| , American Academy of Dermatology, , Johnson & Johnson,

DermWireTV: Sunscreen Ratings, Long Live Skin Launches, SCALE Highlights

Consumer Reports says that one-third of sunscreens tested in its latest evaluation provided less than half of the SPF protection touted on the label. For its part, the American Academy of Dermatology is reminding patients that sunscreen ingredients are safe. The Environmental Working Group continues to caution consumers about “worrisome” ingredients in sunscreen formulations. CVS is launching the Long Live Skin campaign with a focus on sun safety during Skin Cancer Awareness month. In conjunction, Johnson & Johnson will donate $1 to the American Cancer Society for every Neutrogena or Aveeno product with SPF 15 or higher purchased from June 18-24. The Music City SCALE meeting has completed its 12th annual gathering in Nashville. People who smile are actually perceived as older than those with a deadpan or surprised expression, according to a study published in Psychonomic Bulletin and Review.

Watch Video

Wednesday, May 03, 2017

DermWireTV: Skin Cancer Prevention, Mohs Data, Allergan Closes on Zeltiq

It's Skin Cancer Awareness Month. Joel L. Cohen, MD and Shadi Kourosh, MD share tips on patient education and skin protection. Plus, new data set the stage for developing best practices for Mohs micrographic surgery. Wendy Lewis offers tips for digital marketing success. Plus, Allergan closes the deal on Zeltiq.

Watch Video

Tuesday, April 25, 2017

DermWireTV: AAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing

It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAAD shows. In the Phase 3 ALCANZA trial, Seattle Genetics’ and Takeda’s ADCETRIS was associated with a statistically significant improvement in the objective response rate in subjects with CTCL. Valeant Pharmaceuticals’ SILIQ injection of brodalumab will be priced at $3,500 per month, making it the least expensive injectable biologic psoriasis treatment currently on the market, the company says.

Watch Video

Thursday, April 13, 2017

DermWireTV: Rhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale

Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash. Hollywood has a “tendency to depict skin disease in an evil context,” authors of a new JAMA Dermatology analysis of famous movie heroes and villains conclude. PLUS: An update on anti-MOC efforts, with comment from H.L. Greenberg, MD.

Watch Video

Wednesday, March 29, 2017

DermWireTV: Dupixent, Juvéderm Vollure XC, Bavencio Approvals

The FDA has approved Regeneron’s injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan’s Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. EMD Serono’s Bavencio (avelumab) has received FDA fast-track approval for treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. And research shows no significant difference in outcomes when topical or oral antibiotics are added to standard eczema treatment with steroid creams and emollients.

Watch Video

Thursday, March 16, 2017| , AAD, , Galderma, , Modernizing Medicine,

DermWireTV: AAD SkinSerious Campaign, Meeting Highlights; Galderma Partners with Modernizing Medicine

The American Academy of Dermatology’s new SkinSerious campaign is raising awareness about skin disease and the specialty. The Skin Serious initiative kicked off at the AAD Annual Meeting in Orlando this month. New research presented at this year’s meeting focused on skin disease prevention and treatment. Galderma and Moderning Medicine are teaming up for a new integrated OTC ecommerce platform designed by Modernizing Medicine to make it easier for healthcare providers to create materials about patient treatment regimens and provide product recommendations to patients. Pershing Square Capital Management—for which Bill Ackman is CEO—has sold its investment in Valeant Pharmaceuticals International.

Watch Video

Thursday, February 23, 2017

DermWireTV: Valeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging

The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitochondria, a new non-invasive imaging technique, may accurately detect skin cancer without surgical biopsy. And we'll see you at the AAD.

Watch Video

Wednesday, February 08, 2017| , Galderma, , Valeant NJ, , Zeltiq,

Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa

Galderma’s Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics’ CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva Medical. Valeant Dermatology will be awarding nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program.

Watch Video

Thursday, January 26, 2017

DermWireTV: Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10

The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking up to 10 years younger. Research from Johnson & Johnson suggests that the combined use of sunscreen and a beach umbrella may be the best bet for skin protection. Sun Pharma is urging patients to “Leave Acne Behind with an awareness campaign for severe recalcitrant nodular acne (SRNA). With more than 6 million syringes sold worldwide, Radiesse from Merz Aesthetics marks its 10-year anniversary this year.

Watch Video

Thursday, January 12, 2017| , L'oreal, , Valeant NJ,

DermWireTV: L'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking

Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell its CeraVe, AcneFree, and Ambi lines to L’oreal for 1.3 billion dollars in cash. Kérastase and Withings nabbed this year's International CES Innovation Award with The Kérastase Hair Coach Powered. HiMirror rolled out a new Plus edition. Samsung’s S-Skin “microneedle” patch penetrates the skin with ingredients and simultaneously captures measurements of skin quality.

Watch Video
Load More